Systemic Treatment of Thyroid Cancer: ASCO Guideline

Authors

• Nabil F. Saba, Emory University, Atlanta, GA.
• Nofisat Ismaila, American Society of Clinical Oncology (ASCO), Alexandria, VA.
• Douglas Adkins, Washington University School of Medicine, St Louis, MO.
• Nishant Agrawal, University of Chicago Medical Center, Chicago, IL.
• Neil Akhave, The University of Texas MD Anderson Cancer Center, Houston, TX.
• Erik S. Blomain, Thomas Jefferson, Philadelphia, PA.
• Maria E. Cabanillas, The University of Texas MD Anderson Cancer Center, Houston, TX.
• Amy Chen, City of Hope Cancer Center, Atlanta, GA.
• Thomas J. Galloway, Fox Chase Cancer Center, Philadelphia, PA.
• Guilherme Harada, Hospital Sírio-Libanês, São Paulo, Brazil.
• Dapeng Li, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China.
• Salem I. Noureldine, George Washington University, Washington, DC.
• Joe Scharpf, Cleveland Clinic, Cleveland, OH.
• Lova L. Sun, Penn Medicine, Philadelphia, PA.
• Mei Tang, GBMC Health Care, Towson, MD.
• Lori Wirth, Massachusetts General Hospital, Boston, MA.
• Francis Worden, University of Michigan Rogel Cancer Center, Ann Arbor, MI.
• Dan P. Zandberg, UPMC Hillman Cancer Center, Pittsburgh, PA.
• Beth M. Beadle, Stanford University, Stanford, CA.

Document Type

Journal Article

Publication Date

4-1-2026

Journal

Journal of clinical oncology : official journal of the American Society of Clinical Oncology

DOI

10.1200/JCO-26-00235

Abstract

PURPOSE: To provide evidence-based recommendations on the use of systemic therapy in different types of thyroid cancers. METHODS: The American Society of Clinical Oncology convened a multidisciplinary Expert Panel to evaluate the evidence and formulate recommendations. The literature search included studies published between January 1, 2000, and November 5, 2025, and comprised systematic reviews, meta-analyses, randomized controlled trials, and observational studies. Outcomes of interest included overall survival, disease-free survival, and safety. Expert Panel members used available evidence and informal consensus to develop evidence-based guideline recommendations. RESULTS: A total of 66 publications were identified to inform the evidence base for this guideline. RECOMMENDATIONS: Evidence-based recommendations address the use of systemic therapy in patients with well-differentiated, differentiated high-grade or poorly differentiated, anaplastic, and medullary thyroid cancer.Additional information is available at https://ascopubs.org/topics/asco-guidelines/head-neck-cancer.

APA Citation

Saba, Nabil F.; Ismaila, Nofisat; Adkins, Douglas; Agrawal, Nishant; Akhave, Neil; Blomain, Erik S.; Cabanillas, Maria E.; Chen, Amy; Galloway, Thomas J.; Harada, Guilherme; Li, Dapeng; Noureldine, Salem I.; Scharpf, Joe; Sun, Lova L.; Tang, Mei; Wirth, Lori; Worden, Francis; Zandberg, Dan P.; and Beadle, Beth M., "Systemic Treatment of Thyroid Cancer: ASCO Guideline" (2026). GW Authored Works. Paper 9150.
https://hsrc.himmelfarb.gwu.edu/gwhpubs/9150

Department

Surgery